Electronic Supplementary Material (ESI) for Organic Chemistry Frontiers. This journal is © the Partner Organisations 2016

Supporting Information

Visible Light Mediated Aerobic Radical C-H Phosphorization

toward Arylphosphonates

Pan Peng, Long Peng, Guangyu Wang, Fangyu Wang, Yi Luo and Aiwen Lei*

aiwenlei@whu.edu.cn

Table of Contents


General information				
Experim	ental section	3		
1)	General Procedure for Preparation of Benzothiazoles ^[1]	3		
2)	General Procedure for Preparation of Phosphine Oxides ^[2]	3		
3)	Mechanism Study	4		
4)	Procedure and analytical data of compounds 3aa-3ah	5		
Reference	ces]	0		
NMR Sp	pectra of Products	11		

General information

All reactions were run under air atmosphere with a dry air balloon fitted on a Schlenk tube. Unless otherwise noted, materials were obtained from commercial suppliers and used without further purification. Thin layer chromatography (TLC) employed glass 0.25 mm silica gel plates. Flash chromatography columns were packed with 200-300 mesh silica gel. EPR spectra were recorded on a Bruker A-200 spectrometer. HPLC yields were recorded with a DIONEX P680 HPLC Pump. All new compounds were characterized by ¹H NMR, ¹³C NMR and HRMS. High resolution mass spectra (HRMS) were measured with a Thermo Fisher Scientific LTQ FT Ultra. The known compounds were characterized by ¹H NMR, ¹³C NMR. ¹H and ¹³C NMR data were recorded with ADVANCE III 400 MHz spectrometers with tetramethylsilane as an internal standard. All chemical shifts (δ) were reported in ppm and coupling constants (*J*) in Hz. All chemical shifts were reported relative to tetramethylsilane (0 ppm for ¹H), and CDCl₃ (77.16 ppm for ¹³C), respectively.


Experimental section

1) General Procedure for Preparation of Benzothiazoles^[1]



A 50 mL Schlenk tube was charged with 2-aminobenzothiazole derivative (6.5 mmol) and 10 mL of THF, and then isoamyl nitrite (14.3 mmol) was added slowly into the solution. The resultant mixture was refluxed for 30 minutes, and poured into ice-water, and the resultant aqueous mixture was extracted with ethyl acetate (3×30 mL). The organic extracts were combined and washed with brine, dried over MgSO₄, filtered, concentrated in vacuum and purified by column chromatography, giving the desired benzothiazoles in similar yields with the reported procedure.

2) General Procedure for Preparation of Phosphine Oxides^[2]




Phenylmagnesium bromide was prepared from aryl bromides (32.6 mmol) and magnesium (0.95 g, 39.6 mmol). Diethylphosphite (1.29 mL, 10.0 mmol) was added dropwisely to a solution of

phenylmagnesium bromide at 0 °C. The mixture was aged for 15 minutes at 0 °C, then stirred at ambient temperature for two hours. After that cooled again to 0 °C, and 75 mL NH₄Cl aqueous was added slowly. The mixture was extracted with diethyl ether. Washed the organic phase with NaHCO₃ aqueous and brine, then dried over with Na₂SO₄. After the solvent was completely removed under vacuum, the residue was purified by column chromatography on silica gel using petroleum ether/ethyl acetate = 1/1 as eluent to give the product.

3) Mechanism Study

3.1 Radical Trapping Experiment

Diphenylphosphine oxide 2a (121.3 mg, 0.6 mmol), TEMPO (93.8 mg, 0.6 mmol) and Na₂Eosin Y (4.2 mg, 0.006 mmol) was added to Schlenk tube equipped with a stir bar, a balloon filled with dry air was connected to the Schlenk tube through the side arm and purged one time. Then, benzothiazole 1a (23.6 mg, 0.2 mmol), CHCl₃ (1.0 mL) was injected in the reaction tube with magnetic stirring. The reaction mixture was allowed to stir at room temperature under 23w white light for 16 h. The result was detected by HPLC.



3.2 "Light/dark" experiments over the time.

We determined the reaction yield at different time with or without visible light at the standard condition. The yield was determined by ³¹P NMR analysis using OPPh₃ as internal standard.

Time / h	0	4	6	10	12	16
Yield / %	0	12	12	34	34	55

Table 1 "Light/dark" experiments over the time.




Fig. 1 "Light/dark" experiments over the time.

3.3 General Procedure for the Electron Paramagnetic Resonance (EPR) Experiment

Typical procedure: Diphenylphosphine oxide **2a** (121.3 mg, 0.6 mmol) and Na₂Eosin Y (4.2 mg, 0.006 mmol) was added to Schlenk tube equipped with a stir bar, a balloon filled with dry air was connected to the Schlenk tube through the side arm and purged one time. CHCl₃ (1.0 mL) was injected in the reaction tube with magnetic stirring. The reaction mixture was allowed to stir at room temperature under 23 w white light for 1 h, followed by the addition of 10 ul DMPO and stir at room temperature under 23 w white light for 5 min. Then, this reaction was taken out by capillary and was analyzed by EPR at room temperature. This result was shown in Figure 2.





Fig. 2 The electron paramagnetic resonance (EPR) spectra (X band, 9.4 GHz, room temperature)


4) Procedure and analytical data of compounds 3aa-3ah



Benzo[d]thiazol-2-yldiphenylphosphine oxide (**3aa**):^[3] Typical procedure: Diphenylphosphine oxide **2a** (121.3 mg, 0.6 mmol) and Na₂Eosin Y (4.2 mg, 0.006 mmol) was added to Schlenk tube equipped with a stir bar, a balloon filled with dry air was connected to the Schlenk tube through the side arm and purged one time. Then, benzothiazole **1a** (23.6 mg, 0.2 mmol), CHCl₃ (1.0 mL) was injected in the reaction tube with magnetic stirring. The reaction mixture was allowed to stir at room temperature under 23w white light for 16 h. Thereafter, the reaction organic layers were concentrated under reduced pressure. The residue was separated on a silica gel column with petroleum ether (60-90 °C), ethyl acetate (2:1) as eluent to afford the desired product. ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, *J* = 8.2 Hz, 1H), 8.00-7.95

(m, 5H), 7.57-7.49 (m, 8H). ¹³C NMR (101 MHz, CDCl₃) δ 166.8 (d, $J_{C-P} = 127.5$ Hz), 155.4 (d, $J_{C-P} = 21.5$ Hz), 136.8, 132.7 (d, $J_{C-P} = 2.8$ Hz), 132.0 (d, $J_{C-P} = 10.2$ Hz), 131.0 (d, $J_{C-P} = 108.9$ Hz), 128.7 (d, $J_{C-P} = 12.8$ Hz), 126.8, 126.7, 124.8, 122.2. ³¹P NMR (162 MHz, CDCl₃) δ 20.11.

(6-Methoxybenzo[d]thiazol-2-yl)diphenylphosphine oxide (3ba):^[3] The synthesis procedure is the same as for 3aa. ¹H NMR (400 MHz, CDCl₃) δ 8.07-8.05 (m, 1H), 7.98-7.93 (m, 4H), 7.57 (t, *J* = 7.4 Hz, 2H), 7.52-7.48 (m, 4H), 7.42 (s, 1H), 7.16-7.14 (m, 1H), 3.90 (d, *J* = 1.4 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 163.4 (d, *J*_{*C*·*P*} = 130.5 Hz), 159.0, 150.3 (d, *J*_{*C*·*P*} = 22.0 Hz), 138.8, 132.7 (d, *J*_{*C*·*P*} = 2.8 Hz), 132.0 (d, *J*_{*C*·*P*} = 10.2 Hz), 131.3 (d, *J*_{*C*·*P*} = 108.9 Hz), 128.8 (d, *J*_{*C*·*P*} = 12.8 Hz), 125.4, 117.3, 103.5, 56.0. ³¹P NMR (162 MHz, CDCl₃) δ 20.00.




(6-Methylbenzo[d]thiazol-2-yl)diphenylphosphine oxide (3ca):^[3] The synthesis procedure is the same as for 3aa. ¹H NMR (400 MHz, CDCl₃) δ 8.06 (d, *J* = 8.5 Hz, 1H), 7.98 – 7.93 (m, 4H), 7.79 (s, 1H), 7.58 – 7.54 (m, 2H), 7.51 – 7.46 (m, 4H), 7.35 (dd, *J* = 8.5, 1.3 Hz, 1H), 2.50 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 165.3 (d, *J*_{C·P} = 128.4 Hz), 153.7 (d, *J*_{C·P} = 21.7 Hz), 137.2, 137.2, 132.7 (d, *J*_{C·P} = 2.9 Hz), 132.0 (d, *J*_{C·P} = 10.2 Hz), 131.2 (d, *J*_{C·P} = 108.9 Hz), 128.7 (d, *J*_{C·P} = 12.8 Hz), 128.6, 124.3, 121.7, 21.8. ³¹P NMR (162 MHz, CDCl₃) δ 20.18.


(4-Methylbenzo[d]thiazol-2-yl)diphenylphosphine oxide (3da):^[4] The synthesis procedure is the same as for 3aa. ¹H NMR (400 MHz, CDCl₃) δ 8.00-7.98 (m, 4H), 7.80 (d, *J* = 7.8 Hz, 1H), 7.57-7.53 (m, 2H), 7.53 – 7.49 (m, 4H), 7.38-7.31 (m, 2H), 2.77 (s, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 164.9 (d, *J*_{C-P} = 129.0 Hz), 155.0 (d, *J*_{C-P} = 21.1 Hz), 136.7, 134.9, 132.6 (d, *J*_{C-P} = 2.8 Hz), 131.9 (d, *J*_{C-P} = 10.2 Hz), 130.8, 128.6 (d, *J*_{C-P} = 12.8 Hz), 127.0, 126.7, 119.5, 18.5. ³¹P NMR (162 MHz, CDCl₃) δ 19.38.

$$\overset{\mathsf{N}}{\underset{\mathsf{F}}{\overset{\mathsf{O}}{\underset{\mathsf{N}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\underset{\mathsf{P}}{\overset{\mathsf{H}}{\underset{\mathsf{P}}{\atop\mathsf{P}}{\underset{\mathsf{P}}{\underset{\mathsf{P}}{\underset{\mathsf{P}}{\atopP}{\underset{\mathsf{P}}{\atopP}}{\underset{\mathsf{P}}{\underset{\mathsf{P}}{\atopP}}{\underset{\mathsf{P}}{\underset{\mathsf{P}}{\atopP}{\underset{P}}{\underset{\mathsf{P}}{\atopP}{\underset{P}}{\underset{P}}{\underset{P}{\underset{P}}{\underset{$$

(6-Fluorobenzo[d]thiazol-2-yl)diphenylphosphine oxide (3ea):^[3] The synthesis procedure is the same as for 3aa. ¹H NMR (400 MHz, CDCl₃) δ 8.14 (dd, J = 9.1, 4.8 Hz, 1H), 8.16 – 8.12 (m, 4H), 7.68 (dd, J = 8.0, 2.5 Hz, 1H), 7.61 – 7.57 (m, 2H), 7.53 – 7.49 (m, 4H), 7.32 – 7.27 (m, 1H). ¹³C NMR (101 MHz, CDCl₃) δ 166.8 (d, $J_{C-P, C-F} = 126.2, 3.6$ Hz), 161.3 (d, $J_{C-F} = 248.9$ Hz), 152.2 (d, J = 21.8 Hz), 138.1 (d, $J_{C-F} = 11.3$ Hz), 132.8 (d, $J_{C-P} = 2.8$ Hz), 132.0 (d, $J_{C-P} = 10.3$ Hz), 130.8 (d, $J_{C-P} = 109.2$ Hz), 128.8 (d, $J_{C-P} = 12.9$ Hz), 126.0 (d, $J_{C-F} = 9.7$ Hz), 116.0 (d, $J_{C-F} = 25.2$ Hz), 108.1 (d, $J_{C-F} = 26.5$ Hz). ³¹P NMR (162 MHz, CDCl₃) δ 19.93.



(6-Chlorobenzo[d]thiazol-2-yl)diphenylphosphine oxide (3fa):^[5] The synthesis procedure is the same as for 3aa. ¹H NMR (400 MHz, CDCl₃) δ 8.09 (d, *J* = 8.8 Hz, 1H), 7.98 – 7.93 (m, 5H), 7.60-7.57 (m, 2H), 7.53 – 7.48 (m, 5H). ¹³C NMR (101 MHz, CDCl₃) δ 167.9 (d, *J*_{C-P} = 125.1 Hz), 154.0 (d, *J*_{C-P} = 21.6 Hz), 138.1, 133.0, 132.9 (d, *J*_{C-P} = 2.9 Hz), 132.0 (d, *J*_{C-P} = 10.3 Hz), 130.8 (d, *J*_{C-P} = 109.2 Hz), 128.8 (d, *J*_{C-P} = 12.9 Hz), 127.8, 125.6, 121.7. ³¹P NMR (162 MHz, CDCl₃) δ 19.89.




(6-Bromo-1H-inden-2-yl)diphenylphosphine oxide (3ga):^[3] The synthesis procedure is the same as for 3aa. ¹H NMR (400 MHz, CDCl₃) δ 8.15 (d, *J* = 1.8 Hz, 1H), 8.02 (d, *J* = 8.8 Hz, 1H), 7.98-7.93 (m, 4H), 7.63 (dd, J=8.8, 1.9 Hz, 1H), 7.60 – 7.56 (m, 2H), 7.65 – 7.56 (m, 3H), 7.53 – 7.48 (m, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 167.8 (d, *J*_{*C*-*P*} = 124.9 Hz), 154.3 (d, *J*_{*C*-*P*} = 21.5 Hz), 138.5, 132.9 (d, *J*_{*C*-*P*} = 2.9 Hz), 132.0 (d, *J*_{*C*-*P*} = 10.3 Hz), 130.7 (d, *J*_{*C*-*P*} = 109.2 Hz), 130.4, 128.82 (d, *J*_{*C*-*P*} = 12.9 Hz), 125.9, 124.7, 120.9. ³¹P NMR (162 MHz, CDCl₃) δ 19.98.


$$O_2N$$
 N O P P Ph Ph

(6-Nitrobenzo[d]thiazol-2-yl)diphenylphosphine oxide (3ha):^[4] The synthesis procedure is the same as for 3aa. ¹H NMR (400 MHz, DMSO) δ 9.34 (d, *J* = 1.0 Hz, 1H), 8.42 – 8.37 (m, 2H), 7.88 (dd, *J* = 12.6, 7.4 Hz, 4H), 7.70 (t, *J* = 7.1 Hz, 2H), 7.72 – 7.59 (m, 4H). ¹³C NMR (101 MHz, DMSO) δ 174.5 (d, *J*_{C-P} = 118.2 Hz), 157.9 (d, *J*_{C-P} = 20.8 Hz), 145.5, 136.7, 133.3 (d, *J*_{C-P} = 2.7 Hz), 131.5 (d, *J*_{C-P} =


10.3 Hz), 130.1 (d, $J_{C-P} = 108.1$ Hz), 129.2 (d, $J_{C-P} = 12.6$ Hz), 125.1, 122.3, 120.4.³¹P NMR (162 MHz, DMSO) δ 18.49.



Benzo[d]thiazol-2-yldi-p-tolylphosphine oxide (3ab):^[3]The synthesis procedure is the same as for **3aa.** ¹H NMR (400 MHz, CDCl₃) δ 8.18 (d, *J* = 8.1 Hz, 1H), 8.00 (d, *J* = 7.8 Hz, 1H), 7.83 (dd, *J* = 12.5, 8.1 Hz, 4H), 7.55-7.45 (m, 2H), 7.31-7.27 (m, 4H), 2.39 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 167.5 (d, *J*_{*C*·*P*} = 126.2 Hz), 155.4 (d, *J*_{*C*·*P*} = 21.4 Hz), 143.3 (d, *J*_{*C*·*P*} = 2.9 Hz), 136.9, 132.1 (d, *J*_{*C*·*P*} = 10.6 Hz), 129.5 (d, *J*_{*C*·*P*} = 13.2 Hz), 127.8 (d, *J*_{*C*·*P*} = 111.6 Hz), 126.6 (d, *J*_{*C*·*P*} = 7.6 Hz), 124.8, 122.2, 21.8. ³¹P NMR (162 MHz, CDCl₃) δ 20.93.




Benzo[d]thiazol-2-yldi-m-tolylphosphine oxide (**3ac**):^[4] The synthesis procedure is the same as for **3aa.** ¹H NMR (400 MHz, CDCl₃) δ 8.20 (d, *J* = 7.9 Hz, 1H), 8.01 – 7.99 (m, 1H), 7.79 (d, *J*=13.0 Hz, 1H), 7.76 – 7.71(m, 4H), 7.56-7.46 (m, 2H), 7.40-7.36 (m, 4H), 2.37 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 167.2 (d, *J*_{*C*·*P*} = 126.0 Hz), 155.5 (d, *J*_{*C*·*P*} = 21.4 Hz), 138.7 (d, *J*_{*C*·*P*} = 12.7 Hz), 136.9, 133.6 (d, *J*_{*C*·*P*} = 2.9 Hz), 132.3 (d, *J*_{*C*·*P*} = 10.0 Hz), 130.8 (d, *J*_{*C*·*P*} = 108.4 Hz), 129.2 (d, *J*_{*C*·*P*} = 10.5 Hz), 128.6 (d, *J*_{*C*·*P*} = 13.6 Hz), 126.7, 126.6, 124.8, 122.2, 21.5. ³¹P NMR (162 MHz, CDCl₃) δ 20.69.




Benzo[d]thiazol-2-ylbis(4-methoxyphenyl)phosphine oxide (3ad):^[4] The synthesis procedure is the same as for **3aa.** ¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, *J* = 7.8 Hz, 1H), 8.01 – 7.99 (m, 1H), 7.89 – 7.82 (m, 4H), 7.55-7.46 (m, 2H), 7.00 – 6.98 (m, 4H), 3.83 (s, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 167.9 (d,


 $J_{C-P} = 127.0$ Hz), 163.1 (d, $J_{C-P} = 2.9$ Hz), 155.4 (d, $J_{C-P} = 21.3$ Hz), 136.9, 134.0 (d, $J_{C-P} = 11.7$ Hz), 126.6 (d, $J_{C-P} = 10.0$ Hz), 124.8, 122.3 (d, $J_{C-P} = 116.3$ Hz), 122.2, 114.3 (d, $J_{C-P} = 13.9$ Hz), 55.5. ³¹P NMR (162 MHz, CDCl₃) δ 20.74.




Benzo[d]thiazol-2-ylbis(4-fluorophenyl)phosphine oxide (3ae):^[3] The synthesis procedure is the same as for **3aa.** ¹H NMR (400 MHz, CDCl₃) δ 8.20 (d, *J* = 7.8 Hz, 1H), 8.05 – 8.02 (m, 1H), 8.01 – 7.94 (m, 4H), 7.60 – 7.50 (m, 2H), 7.20 (td, *J* = 8.7, 2.4 Hz, 4H). ¹³C NMR (101 MHz, CDCl₃) δ 165.7 (dd, *J*_{*C-P*} = 255.2, 3.1 Hz), 165.1 (dd, *J*_{*C-P*} = 119.9 Hz), 155.4 (d, *J*_{*C-P*} = 21.9 Hz), 136.9, 134.6 (dd, *J*_{*C-P*} = 11.8, 9.0 Hz), 127.0, 126.9 (dd, *J*_{*C-P*} = 113.0, 3.3 Hz), 124.9, 122.3, 116.4 (dd, *J*_{*C-P*} = 21.6, 14.1 Hz). ³¹P NMR (162 MHz, CDCl₃) δ 18.53.



Benzo[d]thiazol-2-ylbis(4-chlorophenyl)phosphine oxide (3af): The synthesis procedure is the same as for **3aa.** ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, *J* = 8.0 Hz, 1H), 8.02 (d, *J* = 7.8 Hz, 1H), 7.94 – 7.88 (m, 8.5 Hz, 4H), 7.58 – 7.47 (m, 6H). ¹³C NMR (101 MHz, CDCl₃) δ 165.6 (d, *J*_{*C-P*} = 130.7 Hz), 155.3 (d, *J*_{*C-P*} = 22.0 Hz), 139.6 (d, *J*_{*C-P*} = 3.5 Hz), 136.7, 133.3 (d, *J*_{*C-P*} = 11.1 Hz), 129.2 (d, *J*_{*C-P*} = 13.5 Hz), 129.2 (d, *J*_{*C-P*} = 111.1 Hz), 127.0, 124.8, 122.2. ³¹P NMR (162 MHz, CDCl₃) δ 18.40. HRMS (ESI+) calculated for C₁₉H₁₃Cl₂NOPS (M+H): 403.9827; found: 403.9825.



Di([1,1'-biphenyl]-4-yl)(benzo[d]thiazol-2-yl)phosphine oxide (3ag): The synthesis procedure is the same as for 3aa. ¹H NMR (400 MHz, CDCl₃) δ 8.22 (d, J = 8.1 Hz, 1H), 8.11 – 8.06 (m, 4H), 8.01 (d, J = 7.8 Hz, 1H), 7.74 – 7.71 (m, 4H), 7.59 – 7.35 (m, 12H).¹³C NMR (101 MHz, CDCl₃) δ 167.0 (d, $J_{C-P} = 127.4$ Hz), 155.4 (d, $J_{C-P} = 21.6$ Hz), 145.5 (d, $J_{C-P} = 2.9$ Hz), 139.8, 136.9, 132.5 (d, $J_{C-P} = 10.6$ Hz), 129.5 (d, $J_{C-P} = 110.5$ Hz), 129.0, 128.3, 127.5 (d, $J_{C-P} = 13.2$ Hz), 127.4, 126.8, 126.7, 124.8, 122.2.³¹P NMR (162 MHz, CDCl₃) δ 20.14. HRMS (ESI+) calculated for C₃₁H₂₃NOPS (M+H): 488.1232; found: 488.1226.




Benzo[d]thiazol-2-yldi(thiophen-2-yl)phosphine oxide (3ah): The synthesis procedure is the same as for **3aa.** ¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, *J* = 8.1 Hz, 1H), 8.01 (d, *J* = 8.0 Hz, 1H), 7.84 – 7.80 (m, 4H), 7.58 – 7.48 (m, 2H), 7.23 – 7.21 (m, 2H).¹³C NMR (101 MHz, CDCl₃) δ 166.3 (d, *J*_{*C*·*P*} = 147.1 Hz), 155.0 (d, *J*_{*C*·*P*} = 24.1 Hz), 137.8 (d, *J*_{*C*·*P*} = 11.2 Hz), 136.8, 135.4 (d, *J*_{*C*·*P*} = 5.8 Hz), 131.7 (d, *J*_{*C*·*P*} = 128.5 Hz), 128.5 (d, *J*_{*C*·*P*} = 15.5 Hz), 127.0, 126.9, 124.9, 122.2.³¹P NMR (162 MHz, CDCl₃) δ 7.00. HRMS (ESI+) calculated for C₁₅H₁₁NOPS₃ (M+H): 347.9735; found: 347.9733.


References


- A. Tsuruoka, Y. Kaku, H. Kakinuma, I. Tsukada, M. Yanagisawa, K. Nara and T. Naito, *Chem. Pharm. Bull.*, 1998, 46, 623-630.
- C. A. Busacca, J. C. Lorenz, N. Grinberg, N. Haddad, M. Hrapchak, B. Latli, H. Lee, P. Sabila, A. Saha, M. Sarvestani, S. Shen, R. Varsolona, X. Wei and C. H. Senanayake, *Org. Lett.*, 2005, 7, 4277-4280.
- 3. H.-J. Zhang, W. Lin, Z. Wu, W. Ruan and T.-B. Wen, *Chem. commun.*, 2015, **51**, 3450-3453.
- 4. K. Luo, Y.-Z. Chen, W.-C. Yang, J. Zhu and L. Wu, Org. Lett., 2016, 18, 452-455.
- X.-L. Chen, X. Li, L.-B. Qu, Y.-C. Tang, W.-P. Mai, D.-H. Wei, W.-Z. Bi, L.-K. Duan, K. Sun, J.-Y. Chen, D.-D. Ke and Y.-F. Zhao, *J. Org. Chem.*, 2014, **79**, 8407-8416.

NMR Spectra of Products

3aa










 $<_{-0.000}^{0.004}$


S13










S16










- 0.000









S22







3ac




S25








3ae




-0.000










---0.000



-20.140

